UBS Asset Management Americas Inc. Acquires 1,303 Shares of PRA Health Sciences, Inc. (PRAH)

UBS Asset Management Americas Inc. lifted its stake in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 6.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,058 shares of the medical research company’s stock after purchasing an additional 1,303 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in PRA Health Sciences were worth $1,655,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 160 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in shares of PRA Health Sciences by 144.0% in the second quarter. Meeder Asset Management Inc. now owns 1,535 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 906 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of PRA Health Sciences by 232.3% in the first quarter. Envestnet Asset Management Inc. now owns 1,844 shares of the medical research company’s stock valued at $121,000 after purchasing an additional 1,289 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new stake in shares of PRA Health Sciences in the first quarter valued at approximately $136,000. Finally, CAPROCK Group Inc. acquired a new stake in shares of PRA Health Sciences in the second quarter valued at approximately $208,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “UBS Asset Management Americas Inc. Acquires 1,303 Shares of PRA Health Sciences, Inc. (PRAH)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/27/ubs-asset-management-americas-inc-boosts-stake-in-pra-health-sciences-inc-prah.html.

Several research firms have issued reports on PRAH. Zacks Investment Research cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Friday, September 15th. SunTrust Banks, Inc. reissued a “buy” rating on shares of PRA Health Sciences in a research note on Wednesday, August 9th. Citigroup Inc. reissued a “buy” rating and set a $93.00 target price (up previously from $90.00) on shares of PRA Health Sciences in a research note on Thursday, August 10th. Robert W. Baird raised their target price on PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $92.00 target price (up previously from $88.00) on shares of PRA Health Sciences in a research note on Thursday, August 10th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. PRA Health Sciences has a consensus rating of “Buy” and an average price target of $86.11.

In other news, VP Linda Baddour sold 100,000 shares of PRA Health Sciences stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $7,485,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Colin Shannon sold 400,000 shares of PRA Health Sciences stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $29,940,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,000,000 shares of company stock worth $748,500,000. 2.10% of the stock is owned by company insiders.

PRA Health Sciences, Inc. (NASDAQ:PRAH) opened at 82.24 on Friday. PRA Health Sciences, Inc. has a 12-month low of $50.87 and a 12-month high of $84.38. The stock has a market capitalization of $5.15 billion, a price-to-earnings ratio of 53.09 and a beta of 0.42. The company has a 50-day moving average price of $78.28 and a 200-day moving average price of $73.83.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 22.71%. The business had revenue of $494.55 million for the quarter, compared to analyst estimates of $477.89 million. During the same period in the previous year, the business earned $0.64 EPS. The firm’s revenue was up 23.7% on a year-over-year basis. On average, equities research analysts forecast that PRA Health Sciences, Inc. will post $3.20 earnings per share for the current year.

PRA Health Sciences Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply